Clinical Trial Update: Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

A Phase 4 study compared Novartis' NVA237 (glycopyrronium) with tiotropium in patients with chronic obstructive pulmonary disease; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-01-01